Skip to main content
Premium Trial:

Request an Annual Quote

Minnesota Researcher Collaborates With Biocept on Bladder, Prostate Cancer Liquid Biopsy Study

NEW YORK (GenomeWeb) – Biocept said today that it will collaborate with University of Minnesota researcher Shilpa Gupta on a study evaluating the company's Target Selector liquid biopsy platform for detection of PD-L1 and androgen receptor (AR) expression in bladder and prostate cancer patients.

Biocept launched its circulating tumor cell-based PD-L1 assay in May and its AR expression test in January.

Gupta, who is a principal investigator in several clinical trials evaluating targeted and immunotherapeutic drugs for prostate and bladder cancers, said in a statement that the tissue biopsies and cystoscopy standardly used for these patients are invasive and can be expensive.

"Biocept's liquid biopsy tests have shown high concordance with tissue biopsies in detecting genetic [alterations] associated with multiple cancers, and this study is aimed at providing additional clinical support for the use of these tests specifically in bladder and prostate cancers," he added.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.